PhD Research in Radiopharmaceuticals, KU Leuven, Belgium

Expires on: 03/05/2024


Embark on a transformative journey in cancer treatment research with the PhD opportunity in “Protein-based Chelators for Targeted Radionuclide Therapy.” This project, commencing March 5th, 2024, explores innovative approaches to enhance the development of radiopharmaceuticals for targeted cancer treatment. As a prospective candidate, you have the chance to contribute to groundbreaking advancements in cancer therapy by integrating protein-based alternatives into the production process, providing new possibilities for targeted radionuclide therapy.

The PhD project aims to enhance the development of radiopharmaceuticals by implementing and benchmarking protein-based alternatives to conventional synthetic chemical chelators. These protein-based alternatives will be directly fused to proteinous carriers, such as peptides or nanobodies, produced recombinantly, and rigorously benchmarked. The research provides a platform for innovation and exploration in targeted radionuclide therapy.


Prospective candidates must hold a Master of Sciences degree with a background in Biology, (Bio)chemistry, or Bio-engineering. The project welcomes individuals with a passion for advancing cancer treatment and exploring novel approaches in the field.


Before applying, candidates are advised to consult the guidelines for the application. Specific document requirements will be detailed in the application guidelines.

Leave a Comment

Your email address will not be published. Required fields are marked *